SMS Lifesciences gets zero USFDA observations for Kazipally facility
Telangana: SMS Lifesciences India has recently announced that the United States Food and Drug Administration (USFDA) has concluded an inspection with zero observations at its API's manufacturing facility located at Kazipally, Jinnaram MandaI, Sangareddy district, Telangana (Unit I ).
"We are glad to inform you that the Company has completed the United States Food and Drug Administration (USFDA) inspection at its API' s manufacturing facility located at Sy. NO.180/2, Kazipally, Jinnaram MandaI, Sangareddy district, Telangana (Unit I ), without any observations," the company said in a BSE filing.
The inspection commenced on 04.04.2022 and concluded on 08.04.2022.
Read also: USFDA okays Alembic Pharma Dabigatran Etexilate Capsules
SMS Lifesciences is a global player in APIs/Intermediates manufacturing having a research and manufacturing team supported by state-of-the-art facilities. What started off as a single facility - single product manufacturing company in 1990 grew to be a multi-location group having products spread across an array of therapeutic segments. SMS Group was given the export house status in the year 1997-98.
Read also: Indoco Remedies bags USFDA nod for Lacosamide Injection
